CN102746175B - 可用作plk1抑制剂的取代的嘧啶并二氮杂* - Google Patents

可用作plk1抑制剂的取代的嘧啶并二氮杂* Download PDF

Info

Publication number
CN102746175B
CN102746175B CN201210030872.3A CN201210030872A CN102746175B CN 102746175 B CN102746175 B CN 102746175B CN 201210030872 A CN201210030872 A CN 201210030872A CN 102746175 B CN102746175 B CN 102746175B
Authority
CN
China
Prior art keywords
methyl
mol
tetrahydro
pyrimido
diazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201210030872.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102746175A (zh
Inventor
蔡建平
陈少清
崔信洁
乐康
建春·托马斯·陆
彼得·米夏埃尔·沃库利希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39415299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102746175(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CN102746175A publication Critical patent/CN102746175A/zh
Application granted granted Critical
Publication of CN102746175B publication Critical patent/CN102746175B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201210030872.3A 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂* Expired - Fee Related CN102746175B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91935807P 2007-03-22 2007-03-22
US60/919,358 2007-03-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2008800088890A Division CN101636399B (zh) 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂*

Publications (2)

Publication Number Publication Date
CN102746175A CN102746175A (zh) 2012-10-24
CN102746175B true CN102746175B (zh) 2014-01-15

Family

ID=39415299

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201210030872.3A Expired - Fee Related CN102746175B (zh) 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂*
CN2008800088890A Expired - Fee Related CN101636399B (zh) 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂*

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2008800088890A Expired - Fee Related CN101636399B (zh) 2007-03-22 2008-03-11 可用作plk1抑制剂的取代的嘧啶并二氮杂*

Country Status (23)

Country Link
US (1) US7517873B2 (cg-RX-API-DMAC7.html)
EP (1) EP2139892B1 (cg-RX-API-DMAC7.html)
JP (1) JP5087640B2 (cg-RX-API-DMAC7.html)
KR (1) KR101157848B1 (cg-RX-API-DMAC7.html)
CN (2) CN102746175B (cg-RX-API-DMAC7.html)
AR (1) AR065794A1 (cg-RX-API-DMAC7.html)
AT (1) ATE524472T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008228303B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0809088A2 (cg-RX-API-DMAC7.html)
CA (1) CA2680757A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008000785A1 (cg-RX-API-DMAC7.html)
CY (1) CY1112102T1 (cg-RX-API-DMAC7.html)
DK (1) DK2139892T3 (cg-RX-API-DMAC7.html)
ES (1) ES2371832T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20110807T1 (cg-RX-API-DMAC7.html)
IL (1) IL200617A (cg-RX-API-DMAC7.html)
MX (1) MX2009010034A (cg-RX-API-DMAC7.html)
PE (1) PE20120495A1 (cg-RX-API-DMAC7.html)
PL (1) PL2139892T3 (cg-RX-API-DMAC7.html)
PT (1) PT2139892E (cg-RX-API-DMAC7.html)
SI (1) SI2139892T1 (cg-RX-API-DMAC7.html)
TW (1) TWI363629B (cg-RX-API-DMAC7.html)
WO (1) WO2008113711A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023269A2 (en) * 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-b[1, 4] diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
AU2008304417B2 (en) * 2007-09-25 2013-07-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CA2700979C (en) * 2007-09-28 2017-06-20 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US20090291938A1 (en) * 2007-11-19 2009-11-26 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
EP2303889A1 (en) * 2008-06-18 2011-04-06 F. Hoffmann-La Roche AG Halo-substituted pyrimidodiazepines as plkl inhibitors
CN103497192B (zh) 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
EP3828185B1 (en) 2009-01-06 2024-11-20 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
PL2442809T3 (pl) 2009-06-17 2017-02-28 Vertex Pharmaceuticals Incorporated Inhibitory replikacji wirusów grypy
JP5763077B2 (ja) 2009-09-14 2015-08-12 ギリアード サイエンシーズ, インコーポレイテッド トール様受容体のモジュレーター
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2014145909A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
EP3024327B1 (en) 2013-07-25 2019-09-04 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
TWI652014B (zh) * 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ, インコーポレイテッド Hivを治療するためのトール様受容体の調節因子
WO2016022902A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
KR20190125537A (ko) 2014-09-16 2019-11-06 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체 조정제의 고체 형태
JP6373490B2 (ja) 2014-09-16 2018-08-15 ギリアード サイエンシーズ, インコーポレイテッド Toll様受容体モジュレーターを調製する方法
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CR20180199A (es) 2015-09-11 2018-05-25 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas
BR112018004618A2 (pt) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. ciano tienotriazoldiazepinas e usos das mesmas
BR112018009798A8 (pt) 2015-11-25 2019-02-26 Dana Farber Cancer Inst Inc inibidores de bromodomínio bivalentes e usos dos mesmos
JP6968819B2 (ja) * 2016-04-07 2021-11-17 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッドDana−Farber Cancer Institute, Inc. ピリミド−ジアゼピノンキナーゼ骨格化合物およびpi3k媒介性障害の治療方法
EP4034132A4 (en) * 2019-09-27 2023-10-11 Dana-Farber Cancer Institute, Inc. Erk5 degraders as therapeutics in cancer and inflammatory diseases
US20230158158A1 (en) * 2020-03-27 2023-05-25 Uppthera Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
WO2022145989A1 (ko) * 2020-12-31 2022-07-07 (주) 업테라 선택적 plk1 억제제로서의 피리미도디아제핀 유도체
WO2023018237A1 (en) * 2021-08-10 2023-02-16 Uppthera, Inc. Novel plk1 degradation inducing compound
GB202313514D0 (en) 2023-09-05 2023-10-18 Cambridge Entpr Ltd Treatment of inflammatory diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390220A (zh) * 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
CN1551881A (zh) * 2001-09-04 2004-12-01 ���ָ��Ӣ��ķ�������Ϲ�˾ 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ570530A (en) * 2006-02-14 2011-09-30 Vertex Pharma Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390220A (zh) * 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
CN1551881A (zh) * 2001-09-04 2004-12-01 ���ָ��Ӣ��ķ�������Ϲ�˾ 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途

Also Published As

Publication number Publication date
JP2010521514A (ja) 2010-06-24
EP2139892A1 (en) 2010-01-06
PT2139892E (pt) 2011-11-21
SI2139892T1 (sl) 2011-12-30
ATE524472T1 (de) 2011-09-15
AU2008228303B2 (en) 2012-04-19
EP2139892B1 (en) 2011-09-14
PE20120495A1 (es) 2012-05-12
PL2139892T3 (pl) 2012-03-30
AR065794A1 (es) 2009-07-01
TW200843781A (en) 2008-11-16
DK2139892T3 (da) 2011-12-12
US20080234255A1 (en) 2008-09-25
CY1112102T1 (el) 2015-11-04
CN101636399A (zh) 2010-01-27
IL200617A0 (en) 2010-05-17
BRPI0809088A2 (pt) 2014-09-09
ES2371832T3 (es) 2012-01-10
CN101636399B (zh) 2012-04-18
CA2680757A1 (en) 2008-09-25
JP5087640B2 (ja) 2012-12-05
KR20090119913A (ko) 2009-11-20
KR101157848B1 (ko) 2012-07-11
TWI363629B (en) 2012-05-11
HRP20110807T1 (hr) 2011-12-31
MX2009010034A (es) 2009-10-12
CL2008000785A1 (es) 2009-03-27
HK1139936A1 (en) 2010-09-30
IL200617A (en) 2014-02-27
WO2008113711A1 (en) 2008-09-25
AU2008228303A1 (en) 2008-09-25
US7517873B2 (en) 2009-04-14
CN102746175A (zh) 2012-10-24

Similar Documents

Publication Publication Date Title
CN102746175B (zh) 可用作plk1抑制剂的取代的嘧啶并二氮杂*
CN108697714B (zh) 稠合嘧啶化合物或其盐
CN104854101B (zh) Alk激酶抑制剂
RU2671494C2 (ru) Некоторые ингибиторы протеинкиназы
TWI764392B (zh) Pi3k抑制劑之鹽及製備方法
CN105121443B (zh) 蛋白激酶抑制剂
WO2020207260A1 (zh) 一种cdk激酶抑制剂及其应用
CN113874015B (zh) Ripk2的噻吩并吡啶抑制剂
EP3768272B1 (en) Jak inhibitors
KR20220006104A (ko) 유비퀴틴화 특이적 프로테아제 억제제 및 이의 제조 방법과 응용
WO2019011228A1 (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
WO2022160931A1 (zh) 吡啶并嘧啶类衍生物及其制备方法和用途
KR20210131372A (ko) Syk 억제제로서의 축합된 피라진의 고체 형태
CN114981270B (zh) Mll1抑制剂和抗癌剂
AU2021410926A9 (en) Tetrahydrothienopyrimidinesulfonamide compounds
CN110914273B (zh) 用于治疗糖尿病的作为pde1抑制剂的[1,2,4]三唑并衍生物
JP2023524935A (ja) 新規なピリミジン誘導体及びこれを含む神経退行性疾患及び癌の予防又は治療用組成物
CN115650974B (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用
WO2024240256A1 (zh) 作为激酶抑制剂的多环化合物及其制备方法和用途
WO2025031358A1 (zh) N2-3-氟-5-取代苯基-2-氨基嘧啶类衍生物、其制备方法及医药用途
JP2024540004A (ja) キナゾリン誘導体化合物およびその用途
BR112017018312B1 (pt) Sais de inibidor de pi3k, composições que as compreende, seu uso, processos para seu preparo e método de inibição de uma atividade de uma quinase pi3k
HK40003732B (zh) 激活素受体样激酶抑制剂
HK1240216B (zh) 蛋白激酶抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140115

Termination date: 20160311

CF01 Termination of patent right due to non-payment of annual fee